CYTOTOXIC LYMPHOCYTE RESPONSES IN ACUTE HIV1 INFECTION
急性 HIV1 感染中的细胞毒性淋巴细胞反应
基本信息
- 批准号:6168427
- 负责人:
- 金额:$ 15.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-05-01 至 2003-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The factors responsible for the initial fall in viremia during acute
HIV-1 infection are incompletely understood. The appearance of HIV-1
specific cytotoxic lymphocytes (CTL) has been temporally correlated with
the decline in viremia, before the appearance of detectable neutralizing
antibodies, suggesting that the cellular immune response may initially
contain viral replication. Alternatively, mathematical modeling
suggests that the decline in viremia is the result of expected
population dynamics of a lymphotropic cytopathic retrovirus, and that
the sharp decline in viremia is a result of diminished numbers of
infectable activated CD4 cells. Almost all studies of CTL responses
during primary infection have been limited to analysis of recognition
of laboratory strains of virus, such that the breadth and specificity
of the initial response is not known. Although recent longitudinal
studies in a single person with primary infection suggest that CTL can
exert immune pressure, as evidenced by the emergence of sequence
variation within a dominant CTL epitope, the ability of CTL or CD8 cells
to actually control replication of the initial virus present has not
been demonstrated. I propose to perform a detailed analysis of the
antiviral cellular immune response in primary HIV-1 infection. We have
developed in vitro assays which allow for the direct examination of
antiviral activity of CD8 cells and CTL clones. We are also developing
an adapted novel technique for the rapid expression of PCR amplified
virus genes using a combination of vaccinia infection-plasmid
transfection, such that responses to autologous virus can be assessed
efficiently. Using these techniques, I will conduct a detailed study
of the antiviral activity of CTL and CD8 cells during the critical
period of primary infection when the viral load is declining, in order
to determine the contribution of the immune system to this decline.
Through a cohort of persons with primary infection in Boston and through
an established and functional collaboration with UCSF, we have access
to blood and tissue specimens from persons during primary infection,
prior to seroconversion and prior to the establishment of the viral set
point. An analysis of the antiviral immune response in these
individuals will provide important information regarding the correlates
of protective immunity and help guide the design of therapeutic
strategies and vaccines. Specifically, I propose to: 1. Characterize
the magnitude, breadth and specificity of the CTL response to autologous
virus in blood and tissues at the time of primary infection, when peak
viremia is declining. 2. Determine the ability of CD8 cells and CTL
clones to inhibit replication of autologous virus at the time of
declining viremia during acute infection.
急性期血病毒血症最初下降的原因
人们对HIV-1感染的了解还不完全。HIV-1病毒的出现
特异性细胞毒性淋巴细胞(CTL)在时间上与
病毒血症的下降,在可检测到的中和出现之前
抗体,这表明细胞免疫反应最初可能
包含病毒复制。或者,数学建模
表明病毒血症的下降是预期的结果
一种嗜淋巴细胞病态逆转录病毒的种群动力学
病毒血症的急剧下降是由于感染病毒的人数减少
易感染的活化的CD4细胞。几乎所有关于CTL反应的研究
在原发感染期间已被局限于识别的分析
实验室病毒株的广度和特异性
最初的反应是什么还不清楚。尽管最近的纵向
对单个原发感染者的研究表明,CTL可以
施加免疫压力,序列的出现证明了这一点
主要CTL表位内的变异,CTL或CD8细胞的能力
要实际控制当前初始病毒的复制还没有
已经被证明了。我建议进行详细的分析
HIV-1原发感染患者的抗病毒细胞免疫反应。我们有
开发的体外检测方法,允许直接检查
CD8细胞和CTL克隆的抗病毒活性。我们也在开发
一种适用于快速表达PCR扩增产物的新技术
利用牛痘病毒感染-质粒组合的病毒基因
转染法,以便可以评估对自体病毒的反应
效率很高。利用这些技术,我将进行详细的研究
关键时期CTL和CD8细胞的抗病毒活性
病毒载量下降的初次感染期,依次为
以确定免疫系统对这种下降的贡献。
通过波士顿的一群初次感染者和通过
与加州大学旧金山分校建立了既定的职能合作,我们可以访问
在初次感染期间对人的血液和组织样本进行检测,
在血清转换之前和在建立病毒集之前
指向。这些疫苗的抗病毒免疫反应分析
个人将提供有关相关人员的重要信息
并帮助指导治疗性免疫系统的设计
战略和疫苗。具体地说,我建议:1.描述
自体CTL反应的大小、广度和特异性
初次感染时血液和组织中的病毒,高峰期
病毒血症正在减少。2.检测CD8细胞和CTL的能力
克隆以抑制自体病毒的复制
急性感染期间病毒血症下降。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robyn S Klein其他文献
West Nile virus: crossing the blood-brain barrier
西尼罗河病毒:穿越血脑屏障
- DOI:
10.1038/nm1204-1294 - 发表时间:
2004-12-01 - 期刊:
- 影响因子:50.000
- 作者:
Michael S Diamond;Robyn S Klein - 通讯作者:
Robyn S Klein
Infectious diseases research in 2024: insights into dementia
2024 年传染病研究:对痴呆症的见解
- DOI:
10.1016/s1474-4422(24)00497-6 - 发表时间:
2025-01-01 - 期刊:
- 影响因子:45.500
- 作者:
Robyn S Klein - 通讯作者:
Robyn S Klein
Robyn S Klein的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robyn S Klein', 18)}}的其他基金
2023 Neuroimmune Communication in Health and Disease Gordon Research Conference and Gordon Research Seminar
2023健康与疾病中的神经免疫通讯戈登研究会议暨戈登研究研讨会
- 批准号:
10609280 - 财政年份:2022
- 资助金额:
$ 15.7万 - 项目类别:
Research Program Award (R35 Clinical Trial Optional) - Dr. Robyn Klein NINDS
研究计划奖(R35 临床试验可选)- Robyn Klein NINDS 博士
- 批准号:
10397683 - 财政年份:2021
- 资助金额:
$ 15.7万 - 项目类别:
Research Program Award (R35 Clinical Trial Optional) - Dr. Robyn Klein NINDS
研究计划奖(R35 临床试验可选)- Robyn Klein NINDS 博士
- 批准号:
10239672 - 财政年份:2021
- 资助金额:
$ 15.7万 - 项目类别:
Astrocyte innate immune mechanisms of post-viral cognitive dysfunction
病毒后认知功能障碍的星形胶质细胞先天免疫机制
- 批准号:
10115451 - 财政年份:2020
- 资助金额:
$ 15.7万 - 项目类别:
Innate immune mechanisms of virologic control and recovery from flavivirus encephalitis
黄病毒脑炎病毒学控制和恢复的先天免疫机制
- 批准号:
10247164 - 财政年份:2020
- 资助金额:
$ 15.7万 - 项目类别:
Mechanisms of sex differences in blood-brain barrier biology
血脑屏障生物学中性别差异的机制
- 批准号:
9090530 - 财政年份:2016
- 资助金额:
$ 15.7万 - 项目类别:
Mechanisms of sex differences in blood-brain barrier biology
血脑屏障生物学中性别差异的机制
- 批准号:
9204440 - 财政年份:2016
- 资助金额:
$ 15.7万 - 项目类别: